Trial Profile

Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277 in Subjects Who Have Completed Study 1001

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peptide p277 (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Andromeda Biotech

Most Recent Events

11 Oct 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
08 Sep 2014 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2014, according to a Hyperion Therapeutics media release.
08 Sep 2014 Planned End Date changed from 1 Jan 2017 to 1 Dec 2014, according to a Hyperion Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com